Annual RA Review — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Reassess csDMARD toxicity risk factors at least annually and adjust laboratory-monitoring frequency to the risk identified
Explanation lettering: C = shown as A · E = shown as B · B = shown as C · A = shown as E
C is correct. The 2025 BSR csDMARD guidance uses a risk-adaptive approach: toxicity risk factors should be reviewed at least annually, with laboratory-monitoring frequency adjusted to the updated risk profile. Relevant considerations include newly developed comorbidity, renal or hepatic impairment, interacting co-prescriptions, alcohol exposure and previous or evolving laboratory abnormalities. Normal results and stable RA do not justify abandoning structured review. Annual surveillance radiographs or MRI are not medication-safety requirements. More broadly, NICE recommends a comprehensive annual RA review, including assessment of disease activity, damage and function; comorbidities such as cardiovascular disease and osteoporosis; complications; life impact; and referral needs. These wider RA-review elements should be addressed, but they do not replace BSR’s specific annual csDMARD toxicity-risk reassessment.
Reference: British Society for Rheumatology. Updated csDMARDs guideline 2025 expands to all ages, 17 November 2025. https://www.rheumatology.org.uk/news/details/Updated-csDMARDs-guideline-2025-expands-to-all-ages